Early and sustained symptom improvement with umeclidinium/vilanterol
Adrenergic beta-2 Receptor Agonists
/ adverse effects
Aged
Benzyl Alcohols
/ adverse effects
Bronchodilator Agents
/ adverse effects
Chlorobenzenes
/ adverse effects
Double-Blind Method
Drug Combinations
Female
Humans
Lung
/ drug effects
Male
Middle Aged
Muscarinic Antagonists
/ adverse effects
Pulmonary Disease, Chronic Obstructive
/ diagnosis
Quinuclidines
/ adverse effects
Recovery of Function
Salmeterol Xinafoate
/ adverse effects
Time Factors
Treatment Outcome
COPD
E-RS:COPD
bronchodilator therapy
rescue medication
symptoms
Journal
Therapeutic advances in respiratory disease
ISSN: 1753-4666
Titre abrégé: Ther Adv Respir Dis
Pays: England
ID NLM: 101316317
Informations de publication
Date de publication:
Historique:
entrez:
29
5
2020
pubmed:
29
5
2020
medline:
2
6
2021
Statut:
ppublish
Résumé
In chronic obstructive pulmonary disease (COPD), both the time needed for patients to gain symptom improvement with long-acting bronchodilator therapy and whether an early response is predictive of a sustained response is unknown. This study aimed to investigate how quickly meaningful symptom responses are seen in patients with COPD with bronchodilator therapy and whether these responses are sustained. Early MAXimisation of bronchodilation for improving COPD stability (EMAX) was a 24-week, double-blind, double-dummy, parallel-group trial that randomised patients to umeclidinium/vilanterol (UMEC/VI), umeclidinium or salmeterol. Daily Evaluating Respiratory Symptoms in COPD (E-RS:COPD) score and rescue salbutamol use were captured In the intent-to-treat population ( Patients with symptomatic COPD had greater potential for early symptom improvements with UMEC/VI NCT03034915, 2016-002513-22 (EudraCT Number).
Sections du résumé
BACKGROUND
In chronic obstructive pulmonary disease (COPD), both the time needed for patients to gain symptom improvement with long-acting bronchodilator therapy and whether an early response is predictive of a sustained response is unknown. This study aimed to investigate how quickly meaningful symptom responses are seen in patients with COPD with bronchodilator therapy and whether these responses are sustained.
METHODS
Early MAXimisation of bronchodilation for improving COPD stability (EMAX) was a 24-week, double-blind, double-dummy, parallel-group trial that randomised patients to umeclidinium/vilanterol (UMEC/VI), umeclidinium or salmeterol. Daily Evaluating Respiratory Symptoms in COPD (E-RS:COPD) score and rescue salbutamol use were captured
RESULTS
In the intent-to-treat population (
CONCLUSION
Patients with symptomatic COPD had greater potential for early symptom improvements with UMEC/VI
CLINICAL TRIAL REGISTRATION
NCT03034915, 2016-002513-22 (EudraCT Number).
Identifiants
pubmed: 32462979
doi: 10.1177/1753466620926949
pmc: PMC7278094
doi:
Substances chimiques
Adrenergic beta-2 Receptor Agonists
0
Benzyl Alcohols
0
Bronchodilator Agents
0
Chlorobenzenes
0
Drug Combinations
0
GSK573719
0
Muscarinic Antagonists
0
Quinuclidines
0
vilanterol
028LZY775B
Salmeterol Xinafoate
6EW8Q962A5
Banques de données
ClinicalTrials.gov
['NCT03034915']
Types de publication
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1753466620926949Références
BMC Pulm Med. 2015 Aug 21;15:97
pubmed: 26293575
Thorax. 2016 Jan;71(1):15-25
pubmed: 26490732
Respir Med. 2014 Dec;108(12):1752-60
pubmed: 25458157
Respir Res. 2014 Oct 07;15:124
pubmed: 25287629
Lancet Respir Med. 2013 May;1(3):199-209
pubmed: 24429126
Chronic Obstr Pulm Dis. 2017 Mar 2;4(2):124-131
pubmed: 28848921
Am J Respir Crit Care Med. 2011 Feb 1;183(3):323-9
pubmed: 20813886
Adv Ther. 2017 Jan;33(12):2188-2199
pubmed: 27796912
Chest. 1984 Jun;85(6):751-8
pubmed: 6723384
Respir Res. 2017 May 8;18(1):86
pubmed: 28482883
Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55
pubmed: 17507545
Pulm Pharmacol Ther. 2018 Apr;49:11-19
pubmed: 29277690
Pulm Pharmacol Ther. 2010 Aug;23(4):257-67
pubmed: 20381630
Respir Med. 1991 Sep;85 Suppl B:25-31; discussion 33-7
pubmed: 1759018
Eur Respir J. 2013 Dec;42(6):1484-94
pubmed: 23722616
Respir Res. 2016 May 23;17(1):61
pubmed: 27215749
Respir Res. 2019 Oct 30;20(1):238
pubmed: 31666084